ScreenerHero

IMMP Immutep Limited

NAS · US · Healthcare · Biotechnology · immutep.com
4.060USD-6.45%Mkt Cap: 29.92M $P/E: —

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap29.92M USD
Enterprise Value-35.85M USD
Revenue (TTM)19.93M USD
Gross Profit-72.01M USD
Net Income (TTM)-79.30M USD
Revenue/Share2.80 USD
Last Price4.060 USD
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.83
PEG—
EV/EBITDA0.45
EV/Revenue-1.80
P/S1.60
P/B14.58
EPS (TTM)-7.30
EPS (Forward)-5.20
52W Range
4.0400% of range70.60
52W High70.60 USD
52W Low4.040 USD
Profitability
Gross Margin0.00%
Oper. Margin-255.74%
EBITDA Margin0.00%
Profit Margin-544.79%
ROE-128.88%
ROA-95.24%
Growth
Revenue Growth633.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-55.46M USD
CapEx (TTM)92.93K USD
FCF Margin-185.58%
FCF Yield-123.66%
Net Debt-67.83M USD
Net Debt/EBITDA0.85
Balance Sheet
Debt/Equity0.02
Current Ratio5.69
Quick Ratio5.54
Book Value/Sh0.30 USD
Cash/Share9.35 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateDec 28, 2016
Splits
Last Split1:20
Split DateSep 28, 2026
Analyst Consensus
Rating—
Target (Mean)30.00 USD
Upside (mean)+638.9%
Target Range30.00 USD – 30.00 USD
# Analysts1
Ownership
Shares Out.7.37M
Float6.89M
Insiders—
Institutions—
Short Interest
Short Ratio3.3d
Short % Float1.40%
Short % Out.0.66%
Shares Short48.56K
Short (prev mo.)38.03K
Technical
SMA 506.831 (-40.6%)
SMA 20021.95 (-81.5%)
Beta2.30
S&P 52W Chg16.45%
Avg Vol (30d)20.22K
Avg Vol (10d)27.30K
Technical Indicators
RSI (14)20.5
MACD-0.8297
MACD Signal-0.7396
MACD Hist.-0.0901
BB Upper7.694 USD
BB Middle5.523 USD
BB Lower3.353 USD
BB Width78.59%
ATR (14)0.4178 USD
Vol Ratio (20d)0.33x